HERA Women’s Cancer Foundation
Sean Patrick Multidisciplinary Collaborative Grant
The HERA Women’s Cancer Foundation provides funds for a project focused on the cause, early
detection, treatment, and/or understanding of ovarian cancer. This annual award provides $50,000 for a
cross-disciplinary project that is collaborative in nature. The application must identify two (or more)
scientists with different yet complementary skills and explain how these skills will be synergistic in
addressing the ovarian cancer problem.
The applications are due July 15, 2014. A single award will be announced in September.
Sean Patrick, for whom this grant was named, was a champion for innovative ovarian cancer research.
She was frustrated by the disproportionate amount of government funds that went to other cancers and
that the traditional chemotherapies had not changed the prognosis of ovarian cancer in decades. To
change this convention, she founded the HERA Women’s Cancer Foundation whose mission is to stop
the loss of women from ovarian cancer by promoting health, empowerment, research, and awareness.
Sean believed that the therapies with the most potential would be formulated by combining great ideas
from different labs and possibly different fields. This grant is in honor of her vision and aims to give
scientists the opportunity to put their heads together and test ideas that may not be fundable by other
More information, such as the kind of grants that HERA supports, can be found at
www.herafoundation.org. Applications and questions should be directed to Meg Steitz, HERA Executive
Director, [email protected], or 970-948-7360.
Scientists and clinicians of non-profit research, medical service, and educational institutions located in the
U.S. are eligible and encouraged to apply.
Application Instructions:
Applications are due July 15, 2014. The applications will be peer reviewed. We will notify the winner in
September. The full application includes one PDF file with the following:
1. One or two completed and signed form(s)/cover page(s), see below. If the research proposed is
performed in two different labs, please submit a face page for each lab. If your application is
chosen to receive the award, HERA will send the amount indicated in the budget (totaling $50K)
to the respective labs/institutions.
2. Include a half-page executive summary of the project that is clear to patients, donors, and
3. Project plan (3 pages): Use 12-point font and 1-inch margins. The project plan should clearly
describe the contribution of each collaborator and the objectives, hypothesis, rationale, relevant
preliminary results, methods, and expected results of the project. Explain how each collaborator’s
skills will be synergistic in addressing the ovarian cancer problem. Explain how the collaboration
or the project is new and, if scientists are at different institutions, how they will work together on
the project. The literature cited does not have to fit in the three-page limit. The application with
the most innovative ideas, that have translational potential, and that develop collaborative
interactions will be favorably reviewed.
4. Detailed budget and budget justification: Funds will only cover direct costs of the project
(reagents and supplies, justifiable expenses, and up to $25K may cover salary support). Indirect
costs are not covered by this award as stated in the HERA bylaws.
Updated 5/2014
5. Include an updated NIH-style biosketch for both PIs with personal statements (include unique
cross-disciplinary strengths) and current and pending support sections (describe overlap or
distinction with current application).
6. Other factors and assurances (from both institutions, if applicable): If the proposed work involves
human subjects, vertebrate animals, or recombinant DNA research, the PI and Institutional
Official must certify that they will adhere to appropriate regulations of the United States Public
Health Service, National Institute of Health, including approval of the study by a properly
constituted Institutional Review Board, Institutional Animal Care and Use Committee, or Biosafety
Committee, respectively.
An electronic copy in a single PDF file of the completed application should be emailed no later
than July 15, 2014 to: [email protected]
If you receive this award:
1. The HERA Women’s Cancer Foundation will contact you regarding information about your
proposal and research for its website, or HERA may use the executive summary with your
approval. HERA may also ask you to participate in an interview that will be posted on HERA’s
2. All publications, abstracts, or similar communications resulting from work supported by the HERA
Women’s Cancer Foundation must acknowledge this support. A PDF of the publication and/or
abstract must be sent to the HERA Foundation.
3. A mid-grant progress report that describes the progress of the research and is clear to a general
audience is due on February 1.
4. A final report that describes the results of the study and is clear to a general audience should be
submitted to HERA within 90-days of project completion. If the funds are not used in the first
year, please contact HERA and a no-cost extension will be approved.
5. After completion of the project, we request your assistance on HERA’s Scientific Advisory Board
for 2 years. These duties include reviewing short grants (like this one) two times per year.
Updated 5/2014
HERA Women’s Cancer Foundation
Sean Patrick Multidisciplinary Collaborative Grant
Cover Page
Applications are due July 15, 2014
______________________FAX: ______________________
Has this project previously been submitted to another agency or organization for funding?
(check one) Yes ______ No ______
If yes, the status of the application must be described, and justification for consideration must be included in the
current/pending support section of the biosketches.
Does this project involve human subjects?
Yes ______
No ______
Does this project involve vertebrate animals?
Yes ______
No ______
Principal Investigator
Institutional Official/Date
Financial Officer
Printed Name
Telephone number / Fax number
Updated 5/2014

HERA Women`s Cancer Foundation